

**Freedom of Information Request – 4157**

I have a Freedom of Information request regarding Biologics and Biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.

\* NB: the table below shows the amount of drug rather than number of patients treated as confirmed in your email dated 4 June 2018.

	<u>Rheumatology</u>	<u>Dermatology</u>	<u>Gastroenterology</u>
Abatacept [Orencia]	73	0	0
Adalimumab [Biosimilar]	0	0	0
Adalimumab [Humira]	3048	170	1645
Apremilast [Otezla]	0	5	0
Baricitinib [Olumiant]	0	0	0
Brodalumab [Kyntheum]	0	0	0
Certolizumab [Cimzia]	782	0	0
Dimethyl fumarate [Skilarence]	0	40	0
Etanercept [Enbrel]	1636	168	0
Etanercept Biosimilar [Benepali or Erelzi]	932	0	0
Golimumab [Simponi]	408	1	0
Guselkumab [Tremfya]	0	0	0
Infliximab [Remicade]	59	0	69
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]	292	0	1408
Ixekizumab [Taltz]	0	0	0
Rituximab [Mabthera]	419	0	0
Rituximab Biosimilar [Rixathon or Truxima]	57	0	2
Sarilumab [Kevzara]	0	0	0
Secukinumab [Cosentyx]	51	10	0
Tocilizumab [Ro Actemra]	647	0	0
Tofacitinib [Xeljanz]	0	0	0
Ustekinumab [Stelara]	0	98	4
Vedolizumab [Entyvio]	0	0	86
<b>Total</b>	<b>8404</b>	<b>492</b>	<b>3283</b>